Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab

Author(s): Carlos A. Canas*, Fabio Bonilla-Abadia, Katherine Vallejo, Hector M. Rengifo, Marco A. Gallon, Gabriel J. Tobon.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 18 , Issue 6 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6).

Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.

Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.

Conclusion: Tocilizumab could be an optional treatment in patients with TAO.

Keywords: Thyroid-associated ophthalmopathy, Graves` associated ophthalmopathy, tocilizumab, IL-6, extrathyroidal manifestation, infiltrating cytokines.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [665 - 667]
Pages: 3
DOI: 10.2174/1871530318666180702150243
Price: $65

Article Metrics

PDF: 48